Life science growth rates
Reporting periods represented: Q1 2026, Q2 2026.
| Company | AVTRAvantor, Inc. | BRKRBruker Corp. | CRLCharles River Laboratories International, Inc. | TMOThermo Fisher Scientific Inc. |
|---|---|---|---|---|
| Reported period | Q2 2026 | Q2 2026 | Q2 2026ended Jun 27, 2026 | Q2 2026ended Jun 27, 2026 |
| Revenue growth organic / non-GAAP, no reconciliation | -0.4% | -0.8% | +0.1% | +5.0% |
Metric coverage
- Revenue growth: 4 of 4 companies report this on the canonical basis.
Oxford Ledge Signal -- extracted from the issuer's own SEC earnings exhibit and normalized by Oxford Ledge. As reported by the issuer per regulatory convention, not re-audited by us; a figure our extractor could not verify is withheld, never shown. A metric is compared only across companies reporting it on the SAME basis and scope; a blank cell is an honest coverage gap, never a zero, and companies may report different quarters (see the period range). Every figure in this table is a CHANGE the issuer reported for the period, not a level. Growth rates and levels never share a column or a table -- a change read as a level is a different number entirely. Organic growth excludes acquisition/divestiture and currency effects as each issuer defines them; definitions are issuer-specific and not audited to a common standard. Source: each issuer’s own SEC EDGAR earnings exhibit.